Fate Therapeutics Inc (FATE) - Net Assets
Based on the latest financial reports, Fate Therapeutics Inc (FATE) has net assets worth $234.07 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($343.67 Million) and total liabilities ($109.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FATE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $234.07 Million |
| % of Total Assets | 68.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -17.09% |
| 10-Year Change | 737.91% |
| Growth Volatility | 50.19 |
Fate Therapeutics Inc - Net Assets Trend (2011–2024)
This chart illustrates how Fate Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore FATE total asset value for the complete picture of this company's asset base.
Annual Net Assets for Fate Therapeutics Inc (2011–2024)
The table below shows the annual net assets of Fate Therapeutics Inc from 2011 to 2024. For live valuation and market cap data, see Fate Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $318.73 Million | -13.49% |
| 2023-12-31 | $368.42 Million | -23.87% |
| 2022-12-31 | $483.94 Million | -28.71% |
| 2021-12-31 | $678.84 Million | +76.58% |
| 2020-12-31 | $384.44 Million | +57.07% |
| 2019-12-31 | $244.76 Million | +52.53% |
| 2018-12-31 | $160.47 Million | +107.89% |
| 2017-12-31 | $77.19 Million | +5.52% |
| 2016-12-31 | $73.15 Million | +92.32% |
| 2015-12-31 | $38.04 Million | +34.22% |
| 2014-12-31 | $28.34 Million | -44.27% |
| 2013-12-31 | $50.85 Million | +196.26% |
| 2012-12-31 | $-52.83 Million | -4.23% |
| 2011-12-31 | $-50.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fate Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 134661800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $114.00K | 0.04% |
| Other Comprehensive Income | $268.00K | 0.08% |
| Other Components | $1.72 Billion | 538.50% |
| Total Equity | $318.73 Million | 100.00% |
Fate Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Fate Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonus Biogroup
TA:BONS
|
$131.51 Million |
|
Soosan Heavy I
KO:017550
|
$131.51 Million |
|
Mercuries Data Systems Ltd
TW:2427
|
$131.62 Million |
|
Korea Fuel-Tech Corporation
KQ:123410
|
$131.70 Million |
|
CPE Technology Berhad
KLSE:5317
|
$131.47 Million |
|
Lara Exploration Ltd.
V:LRA
|
$131.41 Million |
|
Fabryki Mebli Forte S.A.
WAR:FTE
|
$131.39 Million |
|
Dong Hai JSC of Bentre
VN:DHC
|
$131.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fate Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 368,417,000 to 318,726,000, a change of -49,691,000 (-13.5%).
- Net loss of 186,262,000 reduced equity.
- New share issuances of 74,531,000 increased equity.
- Other comprehensive income increased equity by 253,000.
- Other factors increased equity by 61,787,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-186.26 Million | -58.44% |
| Share Issuances | $74.53 Million | +23.38% |
| Other Comprehensive Income | $253.00K | +0.08% |
| Other Changes | $61.79 Million | +19.39% |
| Total Change | $- | -13.49% |
Book Value vs Market Value Analysis
This analysis compares Fate Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-5.72 | $1.53 | x |
| 2012-12-31 | $-5.96 | $1.53 | x |
| 2013-12-31 | $2.57 | $1.53 | x |
| 2014-12-31 | $1.39 | $1.53 | x |
| 2015-12-31 | $1.49 | $1.53 | x |
| 2016-12-31 | $2.30 | $1.53 | x |
| 2017-12-31 | $1.84 | $1.53 | x |
| 2018-12-31 | $2.86 | $1.53 | x |
| 2019-12-31 | $3.59 | $1.53 | x |
| 2020-12-31 | $4.67 | $1.53 | x |
| 2021-12-31 | $7.16 | $1.53 | x |
| 2022-12-31 | $5.00 | $1.53 | x |
| 2023-12-31 | $3.74 | $1.53 | x |
| 2024-12-31 | $2.80 | $1.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fate Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1366.46%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.38x
- Recent ROE (-58.44%) is below the historical average (-44.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -1147.61% | 0.15x | 0.00x | $-8.36 Million |
| 2012 | 0.00% | -533.30% | 0.24x | 0.00x | $-8.96 Million |
| 2013 | -41.09% | -2151.80% | 0.02x | 1.09x | $-25.98 Million |
| 2014 | -91.33% | 0.00% | 0.00x | 1.81x | $-28.72 Million |
| 2015 | -78.85% | -1233.73% | 0.04x | 1.79x | $-33.80 Million |
| 2016 | -45.74% | -760.15% | 0.05x | 1.30x | $-40.78 Million |
| 2017 | -55.65% | -1046.08% | 0.04x | 1.36x | $-50.67 Million |
| 2018 | -41.50% | -1405.02% | 0.02x | 1.33x | $-82.64 Million |
| 2019 | -40.10% | -919.00% | 0.04x | 1.24x | $-122.62 Million |
| 2020 | -45.10% | -551.59% | 0.05x | 1.62x | $-211.83 Million |
| 2021 | -31.25% | -379.89% | 0.06x | 1.36x | $-280.03 Million |
| 2022 | -52.70% | -264.86% | 0.14x | 1.46x | $-303.45 Million |
| 2023 | -43.68% | -253.30% | 0.13x | 1.37x | $-197.77 Million |
| 2024 | -58.44% | -1366.46% | 0.03x | 1.38x | $-218.13 Million |
Industry Comparison
This section compares Fate Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fate Therapeutics Inc (FATE) | $234.07 Million | 0.00% | 0.47x | $131.50 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more